An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors

Trial Profile

An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs RXDX 105 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Ignyta; Teva Pharmaceutical Industries
  • Most Recent Events

    • 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Dec 2016 Preliminary efficacy results (Data cut off 15June 2016, n=74) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 01 Dec 2016 Results published in an Ignyta Inc media release (as of data cut-off, November 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top